Cue Biopharma
CUE
47 hedge funds and large institutions have $6.66M invested in Cue Biopharma in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 11 closing their positions.
0.14% more ownership
Funds ownership: 0.78% → 0.92% (+0.14%)
8% less funds holding
Funds holding: 51 → 47 (-4)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
49% less capital invested
Capital invested by funds: $13M → $6.66M (-$6.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$1.35M |
| 2 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
+$735K |
| 3 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$250K |
| 4 |
AWM
Angeles Wealth Management
Santa Monica,
California
|
+$116K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$57.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$93.3K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$71.6K |
| 3 |
Squarepoint
New York
|
-$61.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$28.4K |
| 5 |
NL
Navalign LLC
Encino,
California
|
-$18K |
CUE Hedge Fund Activity: Q4 2025 in Review
47 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2025, worth a combined $6.66M — down 49% from $13M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CUE and 7 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $1.35M. The largest seller was UBS Group, cutting an estimated $93.3K.
- 47 institutional investors held Cue Biopharma (CUE) as of Q4 2025, down from 51 in Q3 2025.
- Funds reported $6.66M of Cue Biopharma stock for Q4 2025, down 49% quarter-over-quarter.
- 7 funds opened new Cue Biopharma positions in Q4 2025 and 11 closed out, a net change of -4 holders.
- The largest Cue Biopharma buyer in Q4 2025 was Lion Point Capital, an estimated $1.35M added.
- The largest Cue Biopharma seller in Q4 2025 was UBS Group, an estimated $93.3K sold.
Based on aggregated 13F filings for Q4 2025.